Agomelatine is an antidepressant drug with moderate agonistic action at the melatonine
receptor MT1 and weak effect at MT2. According to clinical studies, agomelatine ameliorates
depressive symptoms and improves sleep quality. Side effects such as elevated liver
enzymes are well-known. Therefore, routine laboratory monitoring of liver function
is recommended periodically throughout treatment because of a rare risk of more serious
liver reactions. 2 patients with creatine phosphokinase elevation during treatment
with agomelatine are presented. We recommend a check of the creatine phosphokinase
level during the initial treatment phase in patients receiving agomelatine for the
first time.
Key words
adverse drug reactions - antidepressant drugs - neuropharmacology - psychiatric disorders
